2[2]Levine MN, Bramwell VH, Pritchavd KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J] :J Clin Oncol, 1998; 16: 2651-2658.
3[3]Holmes FA, Walters RS, Theriault RL, et al. Phase Ⅱ trail of paclitaxel,an active drug in the treatmet of metastatic breast cancer[J] .J Natl Cancer Inst, 1991; 83: 1796.
4[4]Clifford A, Hudis and pamela N, Munster. High-Dose therapy for breast cancer[J] .Seminars in Oncology, 1999,26: 35-47.
6Fisher B, Brown AM, Dimotrov NV, et al, Two months of doxoruhicin-cyclophosphamid with and without interval reinduction therapy compared with six months of cyclophosphamid, methotrexate and fluorouracil in positive node of breast cancer patients with tamoxifen nonresponsive tumors: results from NSABPB 15.J Clin Oncol, 1990,8(9):1483
7Fisher B, Jeong JH, Anderson S, et al. Treatment of axillary lymphnode negative, estrogen receptor negative breast cancer;update findings from National Surgical Adjuvant Breast and Bowel Project Clinical Trials. J Natl Cancer Inst, 2004,96(24):1823
8徐兵河．乳腺癌内分泌治疗的策略与评价．上海：复旦大学出版社，2003．843—844
9Smith IE, Dowett M. Aromatase inhibitors in breast cancer. N Engl J Med, 2003,348:2431
